KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Receivables - Other: 2012-2024

Historic Receivables - Other for Supernus Pharmaceuticals (SUPN) over the last 3 years, with Dec 2024 value amounting to $4.0 million.

  • Supernus Pharmaceuticals' Receivables - Other was N/A to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year change of. This contributed to the annual value of $4.0 million for FY2024, which is N/A change from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Receivables - Other stood at $4.0 million for FY2024, which was up 728.16% from $483,000 recorded in FY2013.
  • Supernus Pharmaceuticals' Receivables - Other's 5-year high stood at $4.0 million during FY2024, with a 5-year trough of $4.0 million in FY2024.
  • Moreover, its 1-year median value for Receivables - Other was $4.0 million (2024), whereas its average is $4.0 million.